Intravenous immunoglobulin

Cerebral ischaemia - Intravenous immunoglobulin Factor

Intravenous immunoglobulin is frequently abbreviated as IVIg or IgG (for intravenous gamma globulin).  Immune globulin products from human plasma were first used in 1952 to treat immune deficiency.  Initially, immune globulin products were administered by intramuscular injection.  Intravenous immune globulin was initially shown to be effective in autoimmune idiopathic thrombocytopenic purpura (ITP) in 1981 (Imbach, 1981).

IVIG is used to treat a variety of autoimmune, infectious, and idiopathic diseases.  IVIG is an approved treatment for graft versus host disease and ITP.  It is accepted for use in persons with Kawasaki disease, Guillain-Barré syndrome, and polymyositis/dermatomyositis.

Preliminary questions [37192]

37193 there is some evidence that treatment with intravenous immunoglobulin may be a factor in the development of the condition under consideration, a cerebrovascular accident.

37194 the veteran has been treated with intravenous immunoglobulin at some time.

37195 the veteran was treated with intravenous immunoglobulin within the 72 hours before the clinical onset of the condition under consideration, a cerebrovascular accident.

37196  the veteran was treated with intravenous immunoglobulin for an illness or injury which is identifiable within the 72 hours before the clinical onset of the condition under consideration, a cerebrovascular accident.

37199  the veteran has established the causal connection between treatment with intravenous immunoglobulin and VEA service for the clinical onset of cerebrovascular accident.

37200   the veteran has established the causal connection between treatment with intravenous immunoglobulin and operational service for the clinical onset of cerebrovascular accident.

or

37201   the veteran has established the causal connection between treatment with intravenous immunoglobulin and eligible service for the clinical onset of cerebrovascular accident.

Clinical onset and operational service [37200]

37197  the identified illness or injury, for which the veteran was treated with intravenous immunoglobulin within the 72 hours before the clinical onset of the condition under consideration, a cerebrovascular accident, is causally related to operational service.

Clinical onset and eligible service [37201]

37198  the identified illness or injury, for which the veteran was treated with intravenous immunoglobulin within the 72 hours before the clinical onset of the condition under consideration, a cerebrovascular accident, is causally related to eligible service.